A Phase I Prevention Trial of ACTIVIN Grape Seed Extract as an Aromatase Inhibitor In Healthy Postmenopausal Women at Risk for Breast Cancer
- Determine the efficacy of IH636 grape seed proanthocyanidin extract, in terms of
suppression of estrogen biosynthesis, in healthy post-menopausal women at high risk of
developing breast cancer.
- Determine the safety and tolerability of this dietary supplement, in terms of symptoms
and changes in markers of bone and lipid metabolism and in markers of nonspecific
adrenal suppression, in these participants.
- Determine, preliminarily, an optimum biologic dose of this dietary supplement, as
defined by suppression of serum estradiol, in these participants.
- Determine a minimum duration of use of this dietary supplement to achieve aromatase
inhibition in these participants.
OUTLINE: This is a pilot, dose-finding, placebo-controlled study.
Participants receive oral placebo once or twice daily on days -14 to 0. Participants then
receive oral IH636 grape seed proanthocyanidin extract once or twice daily on days 1-85.
Treatment continues in the absence of toxicity.
Cohorts of 6 participants receive one of four dose levels of IH636 grape seed
proanthocyanidin extract up to an established safe dose.
PROJECTED ACCRUAL: A total of 24 participants will be accrued for this study within 12
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Estrogen suppression as measured by serum estradiol, estrone, estrone sulfate, and sex hormone binding globulin
at 1, 2, 4, 8, and 12 weeks
United States: Institutional Review Board
|City of Hope Comprehensive Cancer Center||Duarte, California 91010|